Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy
M. Yazdimamaghani, O. Kolupaev, C. Lim, D. Hwang, S. Laurie, C. Perou, A. Kabanov, J. Serody
This study shows that combining nanoformulated TLR7/8 agonist and PI3K delta inhibitor with radiotherapy improves anti-tumor activity in TNBC by modulating the tumor microenvironment.
bioRxiv · Mar 9, 2024Immunology